Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Van den Brande

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Seminars in Arthritis and Rheumatism|April 27, 2005
Diverse effects of infliximab and etanercept on T lymphocytesJoachim Sieper, Jan Van Den Brande
Acta Gastro-Enterologica Belgica|August 6, 2014
Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: review and focus on the Belgian situationJan Van den Brande, Aaltje Brouwer, Marc Peeters
The Journal of Rheumatology. Supplement|March 3, 2005
Infliximab induced T lymphocyte apoptosis in Crohn's diseaseJan van den Brande, Daan W Hommes, Maikel P Peppelenbosch
European Heart Journal|April 10, 2014
Giant primary right ventricular synovial sarcomaMichael Wolf, Jan Van den Brande, Inez Rodrigus, et al.
Journal of Cardiac Surgery|June 12, 2018
Primary cardiac synovial sarcoma of the interatrial septumNicolas De Hous, Bernard Paelinck, Jan Van den Brande, et al.
The American Journal of Clinical Nutrition|December 9, 2004
Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell functionHenri Braat, Jan van den Brande, Erik van Tol, et al.
Anti-Cancer Drugs|April 7, 2007
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumorsMarika Rasschaert, Dirk Schrijvers, Jan Van den Brande, et al.
Anti-Cancer Drugs|January 21, 2010
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I studyPol Specenier, Marika Rasschaert, Jan Van den Brande, et al.
American Journal of Clinical Oncology|October 13, 2010
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckPol Specenier, Marika Rasschaert, Philippe Vroman, et al.
Current Treatment Options in Oncology|March 28, 2015
Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancerKonstantinos Papadimitriou, Christian Rolfo, Elien Dewaele, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Seminars in Arthritis and Rheumatism|April 27, 2005
Diverse effects of infliximab and etanercept on T lymphocytesJoachim Sieper, Jan Van Den Brande
Acta Gastro-Enterologica Belgica|August 6, 2014
Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: review and focus on the Belgian situationJan Van den Brande, Aaltje Brouwer, Marc Peeters
The Journal of Rheumatology. Supplement|March 3, 2005
Infliximab induced T lymphocyte apoptosis in Crohn's diseaseJan van den Brande, Daan W Hommes, Maikel P Peppelenbosch
European Heart Journal|April 10, 2014
Giant primary right ventricular synovial sarcomaMichael Wolf, Jan Van den Brande, Inez Rodrigus, et al.
Journal of Cardiac Surgery|June 12, 2018
Primary cardiac synovial sarcoma of the interatrial septumNicolas De Hous, Bernard Paelinck, Jan Van den Brande, et al.
The American Journal of Clinical Nutrition|December 9, 2004
Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell functionHenri Braat, Jan van den Brande, Erik van Tol, et al.
Anti-Cancer Drugs|April 7, 2007
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumorsMarika Rasschaert, Dirk Schrijvers, Jan Van den Brande, et al.
Anti-Cancer Drugs|January 21, 2010
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I studyPol Specenier, Marika Rasschaert, Jan Van den Brande, et al.
American Journal of Clinical Oncology|October 13, 2010
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckPol Specenier, Marika Rasschaert, Philippe Vroman, et al.
Current Treatment Options in Oncology|March 28, 2015
Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancerKonstantinos Papadimitriou, Christian Rolfo, Elien Dewaele, et al.
Pageof 2